XOFLUZA is a 1-dose oral antiviral that shortens flu symptoms to just 2.3 days\textsuperscript{1*}

*Median time vs placebo (54 hours vs 80 hours).

Indication
XOFLUZA\textsuperscript{TM} is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

Most Common Adverse Reactions
Adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects (n=710) who received XOFLUZA at the recommended dose included diarrhea (3%), bronchitis (2%), nausea (1%), nasopharyngitis (1%), and headache (1%).

See full Important Safety Information on page 7. Please read the enclosed full Prescribing Information.
**XOFLUZA:** the first and only 1-dose oral antiviral for the flu

- Just 1 dose of XOFLUZA puts patients on track to be over and done with the flu¹
- All it takes is 1 dose of XOFLUZA to stop viral replication at its source¹

**Drug Interactions**

Co-administration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid co-administration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives or antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

**Important Safety Information**

**Drug Interactions**

- Co-administration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy.
- Avoid co-administration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives or antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

**Concurrent Use with Live Attenuated Influenza Vaccine**

The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

---

¹ See full Important Safety Information on page 7. Please read the enclosed full Prescribing Information.
The flu evolves—an antiviral should too

XOFLUZA has broad-spectrum activity against influenza A and B* viruses, including oseltamivir-resistant strains.1†

A/H1N1, A/H3N2, and influenza B viruses are expected to be the major circulating strains during the 2018-2019 flu season.2

**A/H1N1**

**AVIAN TYPE A/H5N1**

**A/H3N2**

**AVIAN TYPE A/H7N9**

**Type B Viruses**

A/H1N1 H275Y

A/H3N2 E119V

A/H5N1 H275Y

A/H7N9 R292K

Type B D198E

Consider available information on influenza virus types or subtypes and on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

*The number of subjects who received XOFLUZA at the recommended dose and who were infected with influenza type B virus was limited, including 24 subjects in Trial 1 and 38 subjects in Trial 2.

†Antiviral activity was determined against laboratory strains and clinical isolates in vitro. The relationship between antiviral activity and clinical response to treatment in humans has not been established.

**Important Safety Information (cont’d)**

**Most Common Adverse Reactions**

Adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects (n=710) who received XOFLUZA at the recommended dose included diarrhea (3%), bronchitis (2%), nausea (7%), nasopharyngitis (1%), and headache (1%).

See full Important Safety Information on page 7. Please read the enclosed full Prescribing Information.

First-in-class XOFLUZA stops the flu at its source

1-dose XOFLUZA works differently by targeting the flu at its source to stop viral replication.1

There are 5 stages of the viral life cycle in the host cell:

1. **Viral Entry**
2. **Uncoating** & **Budding**
3. **Viral Replication**
4. **Assembly** & **Budding**
5. **Viral Release**

- **M2 ion channel blockers/adamantanes** target viral uncoating in stage 2; however, they are no longer recommended by the CDC due to high resistance.4,6
- **Neuraminidase inhibitors (NAIs), such as oseltamivir**, target the last stage of the viral life cycle: viral release. This prevents the already replicated virus from leaving the host cell.4,5

**XOFLUZA works differently** by targeting the flu earlier at its source, in stage 3. **XOFLUZA inhibits influenza-specific polymerase acidic endonuclease to prevent viral replication.**1,5

**Indication**

XOFLUZA1† is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

**Limitations of Use**

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.
XOFLUZA was as safe and well-tolerated as placebo.

XOFLUZA had a similar or lower adverse event rate than placebo across 2 clinical trials.

INIncidence of adverse events occurring in ≥1% of subjects receiving XOFLUZA or placebo, in the acute uncomplicated influenza trials

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>XOFLUZA (n=710)</th>
<th>Placebo (n=408)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Headache</td>
<td>1%</td>
<td>2%</td>
</tr>
</tbody>
</table>

The safety and efficacy of XOFLUZA have not been established in pediatric subjects under 12 years of age or weighing less than 40 kg.

Importantly Safety Information (cont’d)

Bacterial infections

There is no evidence of efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

References


You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Indication

XOFLUZA†† is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

Limitations of Use

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

Bacterial infections

There is no evidence of efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Drug interactions

Co-administration of polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid co-administration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives or antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

Concurrent use with live attenuated influenza vaccine

The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

Most common adverse reactions

Adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects (n=710) who received XOFLUZA at the recommended dose included diarrhea (3%), bronchitis (2%), nausea (1%), nasopharyngitis (1%), and headache (1%).

For additional important safety information, please see XOFLUZA full prescribing information available at www.XOFLUZA.com.

REFERENCES

**Important Safety Indication**

FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the www.XOFLUZA.com.

Adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects (n=710) who received XOFLUZA at the recommended dose included diarrhea (3%), bronchitis (2%), nausea (1%), nasopharyngitis (1%), and headache (1%).

Most Common Adverse Reactions

- **Drug Interactions**
  - Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.
  - The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.
  - The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

- **Contraindications**
  - XOFLUZA is contraindicated in patients with a known or suspected hypersensitivity to baloxavir marboxil or any of the excipients in XOFLUZA.

- **Warnings and Precautions**
  - Use in Special Populations:
    - **Children**
      - XOFLUZA is not recommended for the treatment of influenza in children under 12 years of age.
    - **Cohorts**
      - XOFLUZA is not recommended for the treatment of influenza in cohorts of institutionalized patients.

- **Recomm Rep.**

References:

3. De Clercq E, Li G. Approved antiviral drugs over the past 50 years.
8. Pay as little as $30* on your XOFLUZA prescription. *Terms and conditions apply.

HELP YOUR PATIENTS SAVE ON XOFLUZA

Eligible patients may pay as little as $30.† No activation required. Terms & Conditions apply.

LEARN MORE ABOUT XOFLUZA AND DOWNLOAD A COUPON AT XOFLUZA.COM/onedose

Patient Eligibility/Terms and Conditions:

1. This offer is valid for eligible patients receiving prescription XOFLUZA. It may be used by those with or without commercial insurance, including patients who choose to pay cash. This offer may not be used for any other product.
2. This offer may not be used by patients in conjunction with prescription insurance under Medicaid, Medicare, TRICARE or similar federal or state programs. This offer is not health insurance or a benefit plan.
3. Offer only valid in the United States and U.S. Territories. This offer is not transferable and may not be combined with any other offer.
4. Offer must be presented along with a valid prescription for XOFLUZA at the time of purchase.
5. The patient or their guardian must be 18 years or older to receive coupon benefits.
6. May be used twice per season. Valid until July 31, 2019.
7. Coupon program is void where prohibited by law and on the date an AB rated generic equivalent for XOFLUZA becomes available.
8. Genentech USA, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. It is a violation of federal law to buy, sell, or counterfeit this offer.

See additional Important Safety Information on page 7. Please read the enclosed full Prescribing Information.